> Academia should be the primary means of drug discovery. Drug manufacturing and distribution _should_ be a commodity business
As mentioned below, the discovery is not the biggest driver of costs.
But you should also ask yourself: why is this not already the case? Currently, there's nothing stopping other countries from using taxpayer money to fund drug development locally. Except, by and large, they don't - as mentioned in the article, most of the drug development that happens worldwide is funded by the United States, even for companies that are headquartered in Europe.
The answer isn't that those countries aren't interested in consuming the benefits of that research, because they are more than willing to purchase those drugs that were developed in the US at lower prices. The answer is that they just choose not to fund the research, either because it's too expensive to conduct clinical trials with taxpayer money, or because it's more effective to have that funded by the market, especially when that market is US patients, rather than European taxpayers.